Drug, Insecticide, and Antimicrobial Resistance

Every chemical tool used against pathogens and their vectors — antibiotics, antivirals, antimalarials, and insecticides — exerts selective pressure that favours organisms able to survive it. Over time this drives the spread of resistant microbes and vectors, eroding the effectiveness of treatment and control. Resistance is therefore not a side issue but a central threat to infectious disease control, elimination, and eradication, capable of reversing hard-won gains.

Definition

Drug, insecticide, and antimicrobial resistance is the heritable ability of microorganisms or vector populations to survive exposure to chemical agents — antibiotics, antivirals, antiparasitics, or insecticides — at concentrations that previously killed or inhibited them, reducing the effectiveness of treatment and vector-control interventions.

Scope

This topic explains how resistance to antimicrobial drugs and to insecticides arises and spreads, why it matters for disease control, and the broad strategies used to slow it, including stewardship, surveillance, infection prevention, and resistance management. It covers the population and programmatic dimensions of resistance; it does not provide antimicrobial selection or dosing advice for individual patients.

Core questions

• How does exposure to antimicrobials and insecticides select for resistant organisms?
• By what mechanisms is resistance acquired and spread?
• What is the population health and disease-control burden of resistance?
• Which strategies can slow the emergence and spread of resistance?

Key concepts

• Selective pressure
• Intrinsic versus acquired resistance
• Horizontal gene transfer
• Cross- and multidrug resistance
• Insecticide resistance mechanisms
• Antimicrobial stewardship
• Resistance surveillance
• One Health

Mechanisms

Resistance arises when genetic variation that allows survival under chemical exposure is selected and propagated. In microbes, resistance can be intrinsic or acquired through mutation or the horizontal transfer of resistance genes on mobile genetic elements, and biochemical mechanisms include enzymatic inactivation of the drug, alteration or protection of its target, reduced uptake, and active efflux. In vectors, insecticide resistance arises through analogous routes, such as target-site mutations and enhanced metabolic detoxification. Because any use of an agent selects for survivors, the rate at which resistance emerges and spreads depends on the volume and appropriateness of use across human health, agriculture, and the environment, linking the problem across sectors under a One Health framing. Strategies to slow resistance therefore combine reducing unnecessary use (stewardship), preventing transmission of resistant organisms (infection prevention and vector management), surveillance to detect resistance early, and rotation or combination of agents to limit selection.

Clinical relevance

Resistance determines whether the treatments and vector-control tools that disease programmes depend on will keep working, and surveillance of resistance informs empirical treatment policy and programme design at a population level. This entry describes resistance as a public-health and disease-control problem and the strategies to contain it; it does not offer guidance on choosing or dosing antimicrobials for any individual.

Epidemiology

Antimicrobial resistance is estimated to be associated with millions of deaths globally each year, with bacterial resistance alone linked to a very large share of infection-related mortality, and regional analyses document substantial attributable death and disability. Resistance also undermines specific control programmes — for example antimalarial drug resistance and insecticide resistance in malaria vectors — illustrating how the erosion of chemical tools threatens both treatment and elimination goals.

History

Resistance has shadowed antimicrobial use since its beginning; Fleming himself warned that misuse of penicillin could select for resistant bacteria, and resistance to early antibiotics appeared within years of their introduction. As resistance accumulated across drug classes and the development of new agents slowed, the problem rose to the top of global health agendas, leading to coordinated responses such as national action plans and a global action plan that frame resistance as a cross-sectoral, One Health challenge requiring stewardship, surveillance, and prevention.

Debates

Stewardship and conservation versus access to antimicrobials

Slowing resistance argues for restricting and rationalising antimicrobial use, yet millions of people die from lack of access to effective drugs; balancing conservation against access — ensuring availability where needed while curbing overuse — is a central and unresolved tension in resistance policy.

Key figures

• Alexander Fleming
• Stuart B. Levy
• Ramanan Laxminarayan
• Helen W. Boucher

Seminal works

• murray-2022
• boucher-2009
• laxminarayan-2016

Frequently asked questions

What is antimicrobial resistance and why is it a public-health problem?

Antimicrobial resistance is the ability of microbes to survive drugs that once killed them. It is a public-health problem because it makes infections harder to treat, raises mortality and cost, and can spread between people, animals, and the environment, threatening the treatments that disease control depends on.

How can the spread of resistance be slowed?

Broadly, by using antimicrobials and insecticides only when needed and appropriately (stewardship), preventing the transmission of resistant organisms through infection prevention and vector management, monitoring resistance through surveillance, and combining or rotating agents to reduce selective pressure. These are coordinated population-level strategies, not individual prescriptions.